berberine/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases alanine aminotransferase
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1“After a 12-week intervention, the BBR group demonstrated a statistically significant decrease in alanine transaminase (ALT) p=0.0105, and de Ritis ratio p=0.0011 compared to the control group.”
Quoted verbatim from Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled trial.. - Study
- RCT
- Duration
- 3 months
- Dose
- berberine 1500 mg/day, oral, 12 weeks
- Population
- adults with metabolic dysfunction-associated fatty liver disease (MAFLD)
Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled trial.2024PMID:39042390Permalink
Keep reading
- Everything the graph holds on berberine
- Every compound studied against Alanine aminotransferase
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M2P9B2T2AF6NMM65YDEHJQWW